Patents Examined by Ruixang Li
  • Patent number: 9527923
    Abstract: Methods of inhibiting platelet aggregation using antibodies having binding specificity for the ? subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing thrombosis in a subject using such antibodies.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: December 27, 2016
    Inventor: Kai Yuan Xu
  • Patent number: 9371368
    Abstract: The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: June 21, 2016
    Assignee: University of Connecticut
    Inventors: Leo Lefrancois, Thomas A. Stoklasek
  • Patent number: 9353186
    Abstract: The neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody blocks prolactin receptor-mediated signalling.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: May 31, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Christoph Freiberg, Christiane Otto, Lars Linden, Axel Harrenga, Mark Trautwein, Simone Greven, Andreas Wilmen
  • Patent number: 8835105
    Abstract: Nucleic acid and protein sequences relating to a cation channel which is sperm-specific (CatSper4) are disclosed. The CatSper4 protein is shown to be specifically expressed in sperm. Nucleic acids, vectors, transformed cells, transgenic animals, polypeptides, and antibodies relating to the CatSper4 gene and protein are disclosed. Also provided are methods of in vitro fertilization and contraception, methods of identifying modulators of CatSper4 activity, methods of genotyping subjects with respect to CatSper4, and methods of diagnosing and treating CatSper4-mediated disorders, including infertility. Related business methods are also disclosed.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: September 16, 2014
    Assignee: Children's Medical Center Corporation
    Inventors: Magdalene M. Moran, Jayhong A. Chong, Ian S. Ramsey, David Clapham